SEC Filing Summary: Synaptogenix, Inc. (SNPX)
Business Context and Reporting Period
This Form 8-K was filed by Synaptogenix, Inc. on June 21, 2021. The registrant is an emerging growth company incorporated in Delaware, with principal executive offices in New York, New York. The report discloses a specific corporate event occurring subsequent to March 31, 2021.
Key Financial Metrics
The filing reports the following financial activity related to the warrant exercises:
- Gross Proceeds: Approximately $3.8 million received from the exercise of warrants.
- Shares Issued: 483,335 shares of common stock ($0.0001 par value) were issued upon exercise.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, net income, operating margins, or cash flow beyond the specific proceeds noted above.
- Debt and Liquidity: The filing text does not provide a clear value for total debt or overall liquidity positions.
Material Changes
The primary material change reported is the increase in outstanding common stock and cash assets resulting from the exercise of 483,335 warrants. This transaction occurred after the end of the fiscal quarter on March 31, 2021.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of specific risks and contingencies beyond the disclosure of the warrant exercise event.
Investor Verification Checklist
- Verify the exact number of shares issued (483,335) and the total gross proceeds ($3.8 million) in the company's subsequent 10-Q or 10-K filings.
- Confirm the impact of this capital raise on the company's total cash position and runway.
- Review the updated share count to assess potential dilution effects on existing shareholders.
- Check for any remaining unexercised warrants and their expiration dates.